A retrospective study to predict a prolonged response to IO or the effects of IO on subsequent TKI treatment in liver cancer patients
Latest Information Update: 29 Jan 2021
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Cemiplimab (Primary) ; Durvalumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
Most Recent Events
- 19 Jun 2020 New trial record
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology